___

• Tanik S, Albayrak S, Zengin K, Borekci H, Bakirtas H, Imamoglu MA et al. Is the neutrophil-lymphocyte ratio an indicator of progression in patients with benign prostatic hyperplasia? Asian Pac J Cancer Prev 2014;15:6375-6379. Karazanashvili G. Editorial comment on: the relationship be- tween prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol 2008; 54:1383-1384.
• Ayyıldız SN, Benli E, Çırakoğlu A, Ayyıldız A. Comparison of serum c-reactive protein levels benign prostate hyperplasia and prostate cancer in patients undergoing prostate biopsy. The New Journal of Urology, 2016; 11: 10-15.
• Ayyıldız SN, Ayyıldız A, Benli E, Çırakoğlu A. Erkeklerde alt üriner sistem semptomları ile C-reaktif protein arasında ilişki var mı? Kesit- sel bir çalışma. JAREM, 2016; 6: 105-109.
• Ayyıldız SN, Ayyıldız A. PSA, PSA derivatives, ProPSA and prostate health index in the diagnosis of prostate cancer. Turk J Urol 2014; 40: 82-88.
• Zlotta AR, Egawa S, Pushkar D, Govorov A, Kimura T, Kido M et al. Prevalence of inflammation and benign prostatic hyperplasia on autopsy in Asian and Caucasian men. Eur Urol 2014; 66: 619-622.
• Asgari SA, Mohammadi M. The role of intraprostatic inflamma- tion in the acute urinary retention. Int J Prev Med 2011; 2: 28-31.
• Partin AW, Carter HB, Chan DW, Epstein JI, Oesterling JE, Rock RC et al. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 1990;143: 747-752.
• Kandirali E, Boran C, Serin E, Semercioz A, Metin A. Association of extent and aggressiveness of inflammation with serum PSA levels and PSA density in asymptomatic patients. Urology 2007; 70: 743-747.
• Poudel B, Mittal A, Shrestha R, Nepal AK, Shukla PS. Prostate biomarkers with reference to body mass index and duration of pros- tate cancer. Asian Pac J Cancer Prev 2012; 13: 2149-2152.
• Oh JJ, Jeong SJ, Lee BK, Jeong CW, Byun SS, Hong SK et al. Does obesity affect the accuracy of prostate-specific antigen (PSA) for predicting prostate cancer among men undergoing prostate biopsy. BJU Int 2013; 112: 265-271.
• Tenório TR, Farah BQ, Ritti-Dias RM, Botero JP, Brito DC, Moura PM et al. Relation between leukocyte count, adiposity, and car- diorespiratory fitness in pubertal adolescents. Einstein 2014; 12: 420-424.
• Singer K, Eng DS, Lumeng CN, Gebremariam A, Lee MJ. The relationship between body fat mass percentiles and inflammation in children. Obesity 2014; 22: 1332-1336.
• Aydin M, Yilmaz A, Donma MM, Tulubas F, Demirkol M, Erdogan M et al. Neutrophil/lymphocyte ratio in obese adolescents. North Clin Istanbul 2015; 2: 87-91.
• Bahadır A, Baltacı D, Türker Y, Türker Y, Iliev D, Öztürk S et al. Is the neutrophil-to-lymphocyte ratio indicative of inflammatory state in patients with obesity and metabolic syndrome? Anatol J Cardiol 2015; 15: 816-822.
• Irani J, Levillain P, Goujon JM, Bon D, Doré B, Aubert J. Inflam- mation in benign prostatic hyperplasia: correlation with prostate specific antigen value. J Urol 1997; 157: 1301-1303.
• Kravchick S, Bunkin I, Peled R, Yulish E, Ben-Dor D, Kravchenko Y et al. Patients with elevated serum PSA and indwelling catheter after acute urinary retention: prospective study of 63 patients with 7-year follow-up. J Endourol 2007; 21: 1203-1206.
• Divella R, De Luca R, Abbate I, Naglieri E, Daniele A. Obesity and cancer: the role of adipose tissue and adipo-cytokines-induced chronic inflammation. J Cancer 2016; 7: 2346-2359.
• Lauterbach MA, Wunderlich FT. Macrophage function in obesity-induced inflammation and insulin resistance. Pflugers Arch 2017; 469: 385-396.
• Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obe- sity. Annu Rev Immunol 2011; 29: 415-445.
• Rocha VZ, Folco EJ. Inflammatory concepts of obesity. Int J Inflam 2011;2011:529061.
• Calle EE, Kaaks R. Overweight, obesity and cancer: epidemio- logical evidence and proposed mechanisms. Nat Rev Cancer 2004; 4: 579-591.
• Parikesit D, Mochtar CA, Umbas R, Hamid AR. The impact of obesity towards prostate diseases. Prostate Int 2016; 4: 1-6.
• Yelsel K, Alma E, Eken A, Gülüm M, Erçil H, Ayyıldız A. Effect of obesity on international prostate symptom score and prostate volume. Urol Ann 2015; 7: 371-374.
• Toriola AT, Laukkanen JA, Kurl S, Nyyssönen K, Ronkainen K, Kauhanen J. Prediagnostic circulating markers of inflammation and risk of prostate cancer. Int J Cancer 2013; 133: 2961-2967.
• De Nunzio C, Kramer G, Marberger M, Montironi R, Nelson W, Schröder F et al. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur Urol 2011; 60: 106-117.
• Gokce MI, Hamidi N, Suer E, Tangal S, Huseynov A, Ibiş A. Evalu- ation of neutrophil-to-lymphocyte ratio prior to prostate biopsy to predict biopsy histology: Results of 1836 patients. Can Urol Assoc J 2015; 9: 761-765.
• Kawahara T, Fukui S, Sakamaki K, Ito Y, Ito H, Kobayashi N et al. Neutrophil-to-lymphocyte ratio predicts prostatic carcinoma in men undergoing needle biopsy. Oncotarget 2015; 6: 32169-32176.
• Ceylan Y, Günlüsoy B, Degirmenci T, Bolat D, Kozacioglu Z, Vardar E et al. Neutrophil-to-lymphocyte and neutrophil-to-monocyte rates in the decision for a prostate re-biopsy in patients with a previous benign pathology and consistently 2,5-10 ng/ml PSA value. Arch Esp Urol 2016; 69: 627-635.
• Wu VJ, Pang D, Tang WW, Zhang X, Li L, You Z. Obesity, age, ethnicity, and clinical features of prostate cancer patients. Am J Clin Exp Urol 2017; 5: 1-9.
• Chamie K, Oberfoell S, Kwan L, Labo J, Wei JT, Litwin MS. Body mass index and prostate cancer severity: do obese men harbor more aggressive disease on prostate biopsy? Urology 2013; 81: 949-955.
• Donmez I, Mungan A. Prevalance of BPH: national realities. Bull Urooncol 2011; 4: 11-14.
• Benli E, Ayyıdız A. The influence of age on localized prostate cancer: Surgical result of paients over 70 years. Bull Urooncol 2014; 13: 54-57.
• Fujita K, Imamura R, Tanigawa G, Nakagawa M, Hayashi T, Kishimoto N et al. Low serum neutrophil count predicts a positive prostate biopsy. Prostate Cancer Prostatic Dis 2012; 15: 386-390.
• Cihan YB, Arslan A, Ergul MA. Subtypes of white blood cells in patients with prostate cancer or benign prostatic hyperplasia and healthy individuals. Asian Pac J Cancer Prev 2013; 14: 4779-4783.
• Gazel E, Tastemur S, Acikgoz O, Yigman M, Olcucuoglu E, Camto- sun A et al. Importance of neutrophil/lymphocyte ratio in prediction of PSA recurrence after radical prostatectomy. Asian Pac J Cancer Prev 2015; 16: 1813-1816.
• Ozer K, Horsanali MO, Gorgel SN, Horsanali BO, Ozbek E. As- sociation between Benign Prostatic Hyperplasia and Neutrophil- Lymphocyte Ratio, an Indicator of Inflammation and Metabolic Syndrome. Urol Int 2017; 98: 466-471.